

Jubilant Drug Development Pte. Limited
Balance Sheet as at 31 March 2020

		USD	INR (In Thousands)	USD	INR (In Thousands)
	Notes	As at 31 March 2020		As at 31 March 2019	
ASSETS					
Non-current assets					
Financial assets					
Investments	1	2,076,349	157,107	2,076,349	143,600
Long-term loans and advances	2	7,009	530	3,690	255
Total non-current assets		2,083,358	157,637	2,080,039	143,855
Current assets					
Financial assets					
Cash and cash equivalents	3	5,229	396	4,284	296
Short-term loans and advances	4	640,000	48,426	640,000	44,262
Other financial assets	5	63,755	4,824	38,085	2,634
Other current assets	6	4,035	305	3,960	274
Total current assets		713,019	53,951	686,329	47,466
Total assets		2,796,377	211,588	2,766,368	191,321
EQUITY AND LIABILITIES					
Equity					
Equity share capital	7	2,547,001	127,332	2,547,001	127,332
Other equity		151,786	76,872	149,149	59,133
Total equity		2,698,787	204,204	2,696,150	186,465
LIABILITIES					
Current liabilities					
Financial liabilities					
Trade payables	8	97,590	7,384	70,218	4,856
Total current liabilities		97,590	7,384	70,218	4,856
Total liabilities		97,590	7,384	70,218	4,856
Total equity and liabilities		2,796,377	211,588	2,766,368	191,321

Benny Thomas
Associate Vice President
Place: Bengaluru
Date: 28 May, 2020

Jubilant Drug Development Pte. Limited
Statement of Profit and Loss for the year ended 31 March 2020

Particulars	Notes	USD	INR (In Thousands)	USD	INR (In Thousands)
		For the year ended 31 March 2020	For the year ended 31 March 2019	For the year ended 31 March 2019	For the year ended 31 March 2019
Other income	9	99,352	7,032	25,600	1,788
Total income		99,352	7,032	25,600	1,788
Expenses					
Other expenses	10	36,967	2,616	13,972	982
Total expenses		36,967	2,616	13,972	982
Profit before tax		62,385	4,415	11,628	806
Tax expense					
- Current tax					
Total tax expense		-	-	-	-
Profit after tax		62,385	4,415	11,628	806
Other comprehensive income					
<i>Items that will not be reclassified to profit or loss</i>					
Exchange differences on translation of foreign operations		-	16,748	-	10,709
Other comprehensive income for the year, net of tax		-	16,748	-	10,709
Total comprehensive income for the year		62,385	21,163	11,628	11,515

Benny Thomas
Associate Vice President
Place: Bengaluru
Date: 28 May, 2020

Jubilant Drug Development Pte. Limited
Statement of changes in Equity for the year ended 31st March 2020

A. Equity Share Capital

	Note	USD	INR (' In Thousands)
Balance as at 1 April 2018	4	2,547,001	127,332
Changes in equity share capital during the year		-	-
Balance as at 31 March 2019	4	2,547,001	127,332
Changes in equity share capital during the year		-	-
Balance as at 31 March 2020	4	2,547,001	127,332

B. Other Equity

	Reserves and surplus						
	Retained earnings		Capital Reserve		Exchange differences on translation of foreign operations	Total	
	USD	INR (In Thousands)	USD	INR (In Thousands)	INR (In Thousands)	USD	INR (In Thousands)
Balance as at 1 April 2018	137,521	40,789	-	-	6,829	137,521	47,618
Profit for the year	11,628	806	-	-	-	11,628	806
Exchange differences on translation of foreign operations	-	-	-	-	10,709	-	10,709
Balance as at 31 March 2019	149,149	41,594	-	-	17,538	149,149	59,133
Profit for the year	62,385	4,415	-	-	-	62,385	4,415
Recognised on account of amalgamation	(1,431,248)	(100,492)	1,371,501	97,068	-	(59,747)	(3,424)
Exchange differences on translation of foreign operations	-	-	-	-	16,748	-	16,748
Balance as at 31 March 2020	(1,219,714)	(54,482)	1,371,501	97,068	34,286	151,787	76,872

Benny Thomas
Associate Vice President
Place: Bengaluru
Date: 28 May, 2020

Jubilant Drug Development Pte. Limited
Statement of Cash Flows for the year ended 31 March 2020

Particulars	USD	INR (In Thousands)	USD	INR (In Thousands)
	For the year ended 31 March 2020		For the year ended 31 March 2019	
A. Cash flow from operating activities				
Profit / loss before tax	62,385	4,415	11,628	806
Adjustments :				
Interest income	(25,670)	(1,817)	(25,600)	(1,788)
Operating cash flow before working capital changes				
Increase/(decrease) in other current assets and loan and advances	4,256	301	(1,927)	(134)
Increase in trade payables and current liabilities	(40,971)	(2,900)	15,899	1,106
Cash (used in) operations	-	-	-	(11)
Income tax paid (net of refund)	-	-	-	-
Net cash (used in) operating activities	-	-	-	(11)
B. Cash flow from investing activities				
Net cash generated from investing activities	-	-	-	-
C. Effect of exchange rate changes		34		28
Net Increase/ (decrease) in cash and cash equivalents (A+B+C)	-	34	-	17
Add: cash and cash equivalents at the beginning of year *	5,230	362	4,284	279
Cash and cash equivalents at the end of the year	5,230	396	4,284	296

* Opening Cash and cash equivalent of Jubilant Biosys (Singapore) Pte. Ltd. added due to Amalgamation.

Benny Thomas
Associate Vice President
Place: Bengaluru
Date: 28 May, 2020

Jubilant Drug Development Pte. Limited
Notes to the financial statements for the year ended 31 March 2020

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2020		As at 31 March 2019	
Note 1. Non-current investments				
Investment in Subsidiary companies				
Jubilant Chemsys Limited	2,076,349	157,107	2,076,349	143,600
1,999,766 (31 March 2019: 1,999,766 of Rs. 10 each)				
	2,076,349	157,107	2,076,349	143,600
Note 2. Long term loan and advances				
Security deposits	7,009	530	3,690	255
	7,009	530	3,690	255
Note 3. Cash and cash equivalent				
Balances with banks:				
- On current accounts	5,229	396	4,284	296
	5,229	396	4,284	296
Note 4. Short-term loans and advances				
Loans to related parties	640,000	48,426	640,000	44,262
	640,000	48,426	640,000	44,262
Note 5. Other financial assets				
Interest recoverable - related parties	63,755	4,824	38,085	2,634
	63,755	4,824	38,085	2,634
Note 6. Other current assets				
Prepaid expenses	4,036	305	3,960	274
	4,036	305	3,960	274

Jubilant Drug Development Pte. Limited
Notes to the financial statements for the year ended 31 March 2020

Note 7: Equity share capital

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2020		As at 31 March 2019	
Issued, subscribed and paid up share capital				
2,547,001 (31 March 2019: 2,547,001 Equity shares with no par value)	2,547,001	127,332	2,547,001	127,332
	2,547,001	127,332	2,547,001	127,332

1). Movement in equity share capital

	Note	No. of shares	USD	INR (' In Thousands)
Balance as at 1 April 2018	7	2,547,001	2,547,001	127,332
Changes in equity share capital during the year				-
Balance as at 31 March 2019	7	2,547,001	2,547,001	127,332
Changes in equity share capital during the year				-
Balance as at 31 March 2020	7	2,547,001	2,547,001	127,332

2) The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.

3) In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

4) The details of shareholders holding more than 5% shares in the company: -

	As at 31 March 2020		As at 31 March 2019	
	No. of shares	% holding in the class	No. of shares	% holding in the class
Name of the Shareholder				
Jubilant Life Science (BVI) Limited	2,547,001	100%	2,547,001	100%

Jubilant Drug Development Pte. Limited
Notes to the financial statements for the year ended 31 March 2020

	USD	INR (In Thousands)	USD	INR (In Thousands)
	As at 31 March 2020		As at 31 March 2019	
Note 8. Trade payables				
Trade payables-others	97,590	7,384	70,218	4,856
	97,590	7,384	70,218	4,856
Note 9. Other income				
Interest Income	25,670	1,817	25,600	1,788
Other non-operating income	73,682	5,215	-	-
	99,352	7,032	25,600	1,788
Note 10. Other expenses				
Auditors remuneration	4,141	293	4,228	295
Legal, professional and consultancy charges	31,406	2,223	9,612	679
Bank charges	298	21	-	-
Foreign exchange loss	1,122	79	133	9
	36,967	2,616	13,972	982